Compared with usual treatment, the use of long-acting injectable antipsychotics significantly increased the time to first hospitalization in patients with early-phase schizophrenia.
The FDA has accepted for filing the supplemental New Drug Application (sNDA) for pimavanserin (Nuplazid®; Acadia) for the treatment of hallucinations and delusions associated with dementia-related psychosis.
Dexmedetomidine is currently available as a solution for intravenous infusion for use in clinical anesthesia and sedation in an intensive care setting.
Adverse events, including voluntary psychiatric admission, suicide attempt, serious violent incident, voluntary admission to a general medical ward, overdose of medication or painkillers, were highest among the combined group compared to the monotherapies.
Psychosis and BPD have previously been linked to persistent nightmares in childhood, and these findings highlight the importance of confronting sleep disturbances at young ages.
A third of patients presented with an altered mental state, including 9 patients with unspecified encephalopathy, 7 with encephalitis, and 23 fulfilling the clinical definition for psychiatric diagnoses.
Predictors of suicide death include male sex, later age at first diagnosis, prior mood disorder diagnosis
Maladaptive cognitive emotion regulation and global emotion dysregulation emerged as mediators of the effects of trauma on depressive and positive symptoms in early nonaffective psychosis.
Acadia Pharmaceuticals has submitted a supplemental New Drug Application to the FDA for pimavanserin (Nuplazid®) for the treatment of hallucinations and delusions associated with dementia-related psychosis.
Data from animal models and postmortem tissue analysis indicate that interneuron dysfunction is an essential feature of schizophrenia.
